Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, By Diagnosis (Imaging Tests and Pancreatic Function Test), Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Drug Type (Generic and Branded), End User (Hospitals, Specialty Clinics, Homecare, Diagnostic Centers, Research and Academic Institute, and Others), Distribution Channel (Direct Tender, Retail Pharmacy, Third Party Distributors, and Others) - Industry Trends and Forecast to 2030.
Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Analysis and Insights
The increasing awareness of advanced diagnostic technology Middle East and Africa has enhanced the demand for the market. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved advancement of processes and techniques also contributes to the rising demand for exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics.
The Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in the developmental activity for launching novel services in the market. The increasing development in advanced healthcare techniques is further boosting the market growth. However, difficulties such as the stringent regulations to hamper the exocrine pancreatic insufficiency (EPI) therapeutic and diagnostic sector, the side effects and religious hurdles associated with pancreatic enzyme replacement therapy (PERT) might hamper the growth of the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the forecast period.
Increasing healthcare expenditure on advancement and development is expected to give opportunities to the market. However, the high cost associated with EPI diagnosis and treatment may challenge the market growth.
Data Bridge Market Research analyzes that the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to reach the value of USD 664.24 million by 2030, at a CAGR of 5.8% during the forecast period.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in Million, Volumes in Units, and Pricing in USD |
|
Segments Covered |
Diagnosis (Imaging Tests and Pancreatic Function Test), Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Drug Type (Generic and Branded), End User (Hospitals, Specialty Clinics, Homecare, Diagnostic Centers, Research and Academic Institute, and Others), Distribution Channel (Direct Tender, Retail Pharmacy, Third Party Distributors, and Others) |
|
Countries Covered |
South Africa, Saudi Arabia, Bahrain, Kuwait, Qatar, Oman, U.A.E., Egypt, Israel, and Rest of Middle East and Africa |
|
Market Players Covered |
EagleBio, AbbVie., Nordmark Arzneimittel GmbH & Co., Digestive Care, Inc., Cilian AG, Alcresta Therapeutics, Inc., ChiRhoClin, Abbott, Bioserv Diagnostics, Laboratory Corporation of America, Organon group of companies Metagenics LLC, Janssen, Nestlé., VIVUS LLC., and ScheBo Biotech AG among others |
Market Definition
Exocrine pancreatic insufficiency (EPI) is a medical condition where the pancreas fails to produce enough digestive enzymes to digest fats, proteins, and carbohydrates in the intestine. EPI can be caused by various conditions, such as chronic pancreatitis, cystic fibrosis, and pancreatic cancer. Therapeutics for EPI involve using pancreatic enzyme replacement therapy (PERT), which provides the necessary digestive enzymes that the pancreas is not producing. PERT is usually taken with meals and snacks to help break down food and absorb nutrients properly; several PERT products are available, such as pancrelipase, pancreatin, and lipase.
Diagnostics for EPI may involve blood tests to measure the levels of digestive enzymes in the blood, fecal elastase test to check the level of pancreatic elastase in the stool, and imaging tests, such as CT scans, MRI, or endoscopic ultrasound to visualize the pancreas and detect any abnormalities. Additionally, breath tests can measure the levels of hydrogen and methane in the breath, indicating EPI.
Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing prevalence of exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis and cystic fibrosis
Exocrine pancreatic insufficiency (EPI) is a condition caused when the pancreas fails to make sufficient amounts of digestive enzymes to help digestion and absorption of nutrients. Chronic pancreatitis is the main cause of EPI in adults. Pancreatitis causes inflammation and swelling of the pancreas. Over time, it can damage the pancreatic cells that make digestive enzymes. Similarly, cystic fibrosis is one of the main causes of EPI in children. It is inherited from parents and causes thick mucus to build up in the lungs, creating difficulty breathing. Mucus also accumulates in the pancreas and prevents digestive enzymes from reaching the small intestine. People with EPI can’t absorb enough fats, proteins, and carbohydrates from foods which is called malabsorption.
Therefore, the increasing prevalence of EPI due to chronic pancreatitis and cystic fibrosis is driving the growth of the market in the forecast period.
- Rising technological advancements in the diagnosis and treatment of EPI
There is a lack of consensus regarding the best diagnostic approach, and experts have noted the non-reliability and non-specificity of available diagnostic tests. Available diagnostic tests for EPI include fecal fat quantification, the fecal elastase-1 test, and the C-mixed triglyceride breath test. Developing a machine learning model that identifies patients in a commercial medical claims database who likely have EPI but are undiagnosed is one of the recent objectives to advance the diagnosis and treatment framework of EPI.
Therefore, the rising technological advancements in the diagnosis and treatment of EPI is driving the market's growth in the forecast period.
Restraint
- Stringent regulations to hamper the exocrine pancreatic insufficiency (EPI) therapeutic and diagnostic sector
The use of therapies and medications for EPI disorders across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases which are preventable by early diagnosis. At the same time, the players of the EPI disorders products manufacturers in the market must follow certain regulations to get approval from the upper authorities for launching the product in the market. These stringent guidelines need to be followed and this is one of the most difficult tasks of all the steps. The U.S. Food and Drug Administration (FDA) regulates the U.S. and the European Union (EU) regulates Europe. However, the rapid development of privacy policies and regulations is being made in the Asia-Pacific and EMEA, including India, Russia, China, South Korea, Singapore, Hong Kong, and Australia. Some drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), have instructed that manufacturers obtain regulatory approvals before marketing their products because of possible adverse effects and inadequate effectiveness. These stringent FDA regulations have made approval of pancrelipase products difficult.
Hence, from the above instances, concluded that stringent regulations may restrain the growth of the exocrine therapeutic insufficiency therapeutics and diagnostics market in the forecast period.
Opportunity
-
Increasing prevalence of pancreatic disorders and associated condition
EPI is a prominent side effect of pancreatic diseases like cancer, cystic fibrosis, and chronic pancreatitis. These ailments can harm the pancreas, impairing its capacity to generate digestive enzymes and result in EPI. The rising prevalence of pancreatic diseases and related ailments worldwide is driving the demand for EPI therapies and diagnostics. These conditions can cause damage to the pancreas, leading to a reduced ability to produce digestive enzymes, which can result in EPI. Cystic fibrosis's damage to the pancreas makes it another disorder that can result in EPI. The genetic disease known as cystic fibrosis impacts the reproductive, digestive, and respiratory systems. Cystic fibrosis is more common in Caucasians, particularly those with a Northern European ancestry, than worldwide. As the incidence of these conditions continues to increase, the demand for EPI therapeutics and diagnostics is also expected to grow. This presents a significant opportunity for pharmaceutical companies and manufacturers to develop new and effective treatments and diagnostic tests for EPI.
Thus, the increasing prevalence of pancreatic disorders and associated conditions is expected to act as an opportunity for market growth.
Challenge
- High cost associated with EPI diagnosis and treatment
The complexity of the illness and the requirement for specialized tests make the diagnosis of EPI expensive. Faecal elastase testing, secretin-stimulated pancreatic function testing, and imaging tests like magnetic resonance imaging (MRI) and endoscopic ultrasonography (EUS) are the most frequently used diagnostic procedures for EPI. These tests can be pricey, and not all medical professionals can access the tools and training needed to carry them out. The high expense of identifying EPI can also delay a diagnosis, which can exacerbate symptoms and raise healthcare costs over time. Untreated EPI can cause continuing digestive problems, nutrient malabsorption, and weight loss in patients, all of which can increase medical expenses and difficulties.
Thus, the high cost associated with EPI diagnosis and treatment is expected to act as a challenge in the market growth.
Recent Developments
- In August 2021, AzurRx announced that it had engaged in the development of yeast-derived lipase, MS1819, which has been engineered to have superior enzymatic activity as compared to current treatments.
- In February 2023, Codexis, Inc. and Nestlé Health Science announced the interim findings from a Phase 1 trial examining the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108. A lipase variation called CDX-7108 was created expressly to get around the drawbacks of the current pancreatic enzyme replacement treatment (PERT). This has aided the business in marketing the product.
Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Scope
The Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is categorized into five notable segments such as diagnosis, treatment, drug type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Diagnosis
- Imaging Tests
- Pancreatic Function Test
On the basis of diagnosis, the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into imaging test and pancreatic function test.
Treatment
- Nutritional Management
- Pancreatic Enzyme Replacement Therapy (PERT)
On the basis of treatment, the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into nutritional management and pancreatic enzyme replacement therapy (PERT).
Drug Type
- Generic
- Branded
On the basis of drug type, the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into generic and branded.
End User
- Hospitals
- Specialty Clinics
- Homecare
- Diagnostic Centre
- Research and Academic Institutes
- Others
On the basis of end user, the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into Hospitals, Specialty Clinics, Homecare, Diagnostic Centers, Research and Academic Institute, and others.
Distribution Channel
- Direct Tender
- Retail Pharmacy
- Third-Party Distributor
- Others
On the basis of distribution channel, the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into direct tender, retail pharmacy, third party distributor, and others.
Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Regional Analysis/Insights
The Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is categorized into five notable segments such as diagnosis, treatment, drug type, end user, and distribution channel.
The countries covered in this market report are South Africa, Saudi Arabia, Bahrain, Kuwait, Qatar, Oman, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
South Africa is dominating due to the presence of key market players in the largest consumer market with high GDP.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share Analysis
Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market competitive landscape provide details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the Middle East and Africa nurse call systems market.
Some of the major players operating in the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are EagleBio, AbbVie. Nordmark Arzneimittel GmbH & Co., Digestive Care, Inc., Cilian AG, Alcresta Therapeutics, Inc., ChiRhoClin, Abbott, Bioserv Diagnostics, Laboratory Corporation of America, Organon group of companies Metagenics LLC, Janssen, Nestlé., VIVUS LLC., and ScheBo Biotech AG, among others.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER ANALYSIS
5 INDUSTRY INSIGHTS
6 REGULATORY FRAMEWORK
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) DUE TO CHRONIC PANCREATITIS AND CYSTIC FIBROSIS
7.1.2 RISING TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSIS AND TREATMENT OF EPI
7.1.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS
7.1.4 SEDENTARY LIFESTYLES AND UNHEALTHY DIETS
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATIONS TO HAMPER THE EXOCRINE PANCREATIC INSUFFICIENCY(EPI) THERAPEUTIC AND DIAGNOSTIC SECTOR
7.2.2 SIDE EFFECTS AND RELIGIOUS HURDLES ASSOCIATED WITH PANCREATIC ENZYME REPLACEMENT THERAPY (PERT)
7.3 OPPORTUNITIES
7.3.1 INCREASING PREVALENCE OF PANCREATIC DISORDERS AND ASSOCIATED CONDITION
7.3.2 RISING AWARENESS ABOUT THE BENEFITS OF EARLY DIAGNOSIS AND TREATMENT OF EPI
7.3.3 GROWING DEMAND FOR COMBINATION THERAPIES AND PERSONALIZED MEDICINE
7.4 CHALLENGES
7.4.1 HIGH COST ASSOCIATED WITH EPI DIAGNOSIS AND TREATMENT
7.4.2 LIMITED AVAILABILITY OF EPI THERAPEUTICS AND DIAGNOSTICS
8 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 PANCREATIC ENZYME REPLACEMENT THERAPY (PERT)
8.2.1 BY ENZYME
8.2.1.1 LIPASE
8.2.1.2 PROTEASE
8.2.1.3 AMYLASE
8.2.2 BY ROUTE OF ADMINISTRATION
8.2.2.1 ORAL
8.2.2.1.1 CAPSULES
8.2.2.1.2 TABLETS
8.2.2.1.3 POWDER
8.2.2.2 INTRAVENOUS
8.3 NUTRITIONAL MANAGEMENT
8.3.1 VITAMIN D
8.3.2 VITAMIN E
8.3.3 VITAMIN A
8.3.4 VITAMIN K
8.3.5 OTHERS
9 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 PANCREATIC FUNCTION TEST
9.2.1 STOOL
9.2.1.1 FECAL ELASTASE TEST
9.2.1.2 FECAL FAT TEST
9.2.2 SECRETIN PANCREATIC FUNCTION TEST
9.2.3 BLOOD TESTS
9.2.4 C-MIXED TRIGLYCERIDES BREATH TEST
9.2.5 FASTING PLASMA GLUCOSE TEST
9.3 IMAGING TEST
9.3.1 CT SCANNING
9.3.2 MAGNETIC RESONANCE IMAGING TESTS (MRI)
9.3.3 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
9.3.4 ENDOSCOPIC ULTRA-SONOGRAPHY (EUS)
9.3.5 SECRETIN-STIMULATED MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY
10 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 BRANDED
10.2.1 CREON
10.2.2 ZENPEP
10.2.3 PANCREAZE
10.2.4 NUTRIZYM
10.2.5 PANCREASE MT
10.2.6 PANCREX
10.2.7 COTAZYM
10.2.8 ULTERSA
10.2.9 VIOKACE
10.2.10 PERTZYE
10.2.11 OTHERS
10.3 GENERIC
11 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PRIVATE
11.2.2 PUBLIC
11.3 SPECIALTY CLINICS
11.4 DIAGNOSTIC CENTER
11.5 HOMECARE
11.6 RESEARCH AND ACADEMIC INSTITUTES
11.7 OTHERS
12 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL PHARMACY
12.4 THIRD PARTY DISTRIBUTORS
12.5 OTHERS
13 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 BAHRAIN
13.1.4 U.A.E.
13.1.5 KUWAIT
13.1.6 OMAN
13.1.7 QATAR
13.1.8 EGYPT
13.1.9 ISRAEL
13.1.10 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBVIE INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 ABBOTT
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 NESTLE
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 LABORATORY CORPORATION OF AMERICA HOLDINGS (2022)
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 JANSSEN MIDDLE EAST AND AFRICA SERVICES, LLC
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ALCRESTA THERAPEUTICS, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 COMPANY SHARE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 BIOSERV DIAGNOSTICS GMBH
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 CILIAN AG
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 CHIRHOCLIN
16.9.1 COMPANY SNAPSHOT
16.9.2 COMPANY SHARE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 DIGESTIVE CARE, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 EAGLEBIO
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 METAGENICS LLC
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 NORDMARK
16.13.1 COMPANY SNAPSHOT
16.13.2 COMPANY SHARE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 ORGANON GROUP OF COMPANIES.
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 SCHEBO BIOTECH AG
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 VIVUS LLC
16.16.1 COMPANY SNAPSHOT
16.16.2 COMPANY SHARE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ENZYME, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA ORAL IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA NUTRITIONAL MANAGEMENT IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA NUTRITIONAL MANAGEMENT IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA PANCREATIC FUNCTION TEST IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA PANCREATIC FUNCTION TEST IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA STOOL IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA IMAGING TESTS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA IMAGING TESTS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA BRANDED IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA BRANDED IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA GENERIC IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA HOSPITALS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA HOSPITALS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA DIAGNOSTIC CENTER IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA HOMECARE IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA RESRACH AND ACADEMIC INSTITUTES IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA OTHERS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA DIRECT TENDER IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA THIRD PARTY DISTRIBUTORS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA OTHERS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) DUE TO CHRONIC PANCREATITIS AND CYSTIC FIBROSIS IS EXPECTED TO DRIVE THE FIGURE 10 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 THE PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET
FIGURE 14 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, 2022
FIGURE 15 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, CAGR (2023-2030)
FIGURE 17 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, 2022
FIGURE 19 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, 2022
FIGURE 23 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 35 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 36 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030)
FIGURE 39 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
